QT
TBPH icon

Quantamental Technologies’s Theravance Biopharma TBPH Stock Holding History

Quantamental Technologies’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,664
Closed -$140K – 547
2021
Q4 		$140K Buy
+12,664
New +$110K 0.07% 355
2019
Q1 		– Sell
-4,000
Closed -$102K – 1768
2018
Q4 		$102K Buy
+4,000
New +$108K 0.06% 544

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Quantamental Technologies's TBPH Position: Q1 2022 in Review

Quantamental Technologies sold out of Theravance Biopharma (TBPH) in Q1 2022, closing a stake of 12,664 shares — an estimated $140K sold.

Quantamental Technologies first reported a position in TBPH in Q4 2018 and held it in 2 quarters. The position peaked at $140K in Q4 2021. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

  • Quantamental Technologies reported no remaining Theravance Biopharma position as of Q1 2022 after selling out during the quarter.
  • Quantamental Technologies sold 12,664 Theravance Biopharma shares in Q1 2022, an estimated $140K.
  • Quantamental Technologies first reported a position in Theravance Biopharma in Q4 2018 and held it in 2 quarters.
  • Quantamental Technologies's Theravance Biopharma position peaked at $140K in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Quantamental Technologies's 13F filing for Q1 2022, filed 16 May 2022.